Literature DB >> 32742709

Correction to: Economic evaluation of AbobotulinumtoxinA vs OnabotulinumtoxinA in real-life clinical management of cervical dystonia.

V P Misra1, N Danchenko2, P Maisonobe2, J Lundkvist3, M Hunger4.   

Abstract

[This corrects the article DOI: 10.1186/s40734-020-0083-0.].
© The Author(s) 2020.

Entities:  

Year:  2020        PMID： 32742709      PMCID： PMC7390106          DOI： 10.1186/s40734-020-00088-5

Source DB:  PubMed          Journal:  J Clin Mov Disord        ISSN： 2054-7072


Correction to: J Clin Mov Disord 7, 2 (2020) https://doi.org/10.1186/s40734-020-0083-0 Following publication of the original article [1], an error was identified in the Cost-per-responder sub-section. The updated conclusion is given below and the changes have been highlighted in bold typeface. The results showed that the adjusted mean total cost-per-responder was lower for patients receiving aboBoNT-A compared to patients receiving onaBoNT-A (€986 vs. €1524), based on the primary treatment response definition.
  1 in total

1.  Economic evaluation of AbobotulinumtoxinA vs OnabotulinumtoxinA in real-life clinical management of cervical dystonia.

Authors:  V P Misra; N Danchenko; P Maisonobe; J Lundkvist; M Hunger
Journal:  J Clin Mov Disord       Date:  2020-02-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.